Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson ’s disease

In this study, we hypothesized that treatment with DPP4 inhibitors may have beneficial effects on nigrostriatal dopamine and longitudinal motor performance in diabetic patients with Parkinson ’s disease. We classified 697 drug naive patients withde novo Parkinson ’s disease who had undergone dopamine transporter imaging into three groups according to a prior diagnosis of diabetes and use of DPP4 inhibitors: diabetic patients with Parkinson’s disease being treated with (n  = 54) or without DPP4 inhibitors (n  = 85), and non-diabetic patients with Parkinson ’s disease (n  = 558). Diabetic patients with Parkinson ’s disease being treated with DPP4 inhibitors had a higher baseline dopamine transporter availability in the anterior (2.56 ± 0.74 versus 2.10 ± 0.50;P  = 0.016), posterior (1.83  ± 0.69 versus 1.40 ± 0.50;P  <  0.001), and ventral putamina (1.72  ± 0.58 versus 1.35 ± 0.37;P  = 0.001) than that in diabetic patients with Parkinson ’s disease without DPP4 inhibitors. Additionally, diabetic patients with Parkinson’s disease being treated with DPP4 inhibitors had higher dopamine transporter availability in the posterior putamen than that in non-diabetic patients with Parkinson’s disease (1.83 ± 0.69 versus 1.43 ±  0.59;P  <  0.001). After adjusting for age, sex, disease duration, and vascular risk factors, linear regression models showed that a prior treatment of DPP4 inhibitors remain...
Source: Brain - Category: Neurology Source Type: research